As above mentioned, TP53 mutations in AML are associated with clearly lower responses to standard chemotherapy and are considered as a strongly negative prognostic marker associated with poor treatment outcomes, including with allogeneic stem cell transplantation [376]. This evidence concerns the gene TP53 and acute myeloid leukemia.